Choose Your News
A panel of European Medicines Agency (EMA) on Friday recommended approval for Pfizer Inc's Zirabev, a cheaper version to Roche Holding AG's leading cancer drug... [Read More]
Daniel Meyer, a lobbyist for Pfizer, Major League Baseball, BP, Bank of New York Mellon, and more than a dozen other large corporations, had an... [Read More]
Dec 14, 2018--The board of directors of Pfizer Inc. today declared a 36-cent first-quarter 2019 dividend on the company's common stock, payable March 1, 2019,... [Read More]
Dec 14, 2018--Pfizer Inc. (NYSE:PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted... [Read More]
Dec 14, 2018--Pfizer Inc. (NYSE:PFE) announced today the initiation of a Phase 3 program for its 20-Valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077, for the... [Read More]
Content provided by Pfizer Inc. [Read More]
The latest on developments in financial markets (all times local): 9:35 a.m. Stocks are off to a solid start on Wall Street as... [Read More]
Pfizer is adding 100 to its oncology research unit in La Jolla. The site has been highly productive for Pfizer. [Read More]
In the past three months, the Food And Drug Administration okayed four anti-cancer drugs developed, in part, at the Pfizer facility in Groton. [Read More]
Time's running out! If you've still got some money sitting in your flexible spending account, you have until the end of the year to use... [Read More]
Baldwin presses Pfizer on price hikes... [Read More]
The included top analyst upgrades, downgrades and initiations seen on Tuesday Apptio, AT&T, Bain Capital, Comerica, First Solar, Palo Alto Networks, Pfizer, Travelers and Ulta... [Read More]
J.P. Morgan downgraded Pfizer shares to neutral from overweight on Tuesday, warning clients that the stock's 2018 run up will likely slow. [Read More]
Pfizer shares slipped lower in pre-market trading Tuesday after analysts at JPMorgan lowered their rating for the drugmaker amid concerns of the loss of exclusivity... [Read More]
A new generation of drugs as well as several other factors could Pfizer could drive PFE stock to all-time highs. [Read More]